Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|August 28, 2020
Axol Bioscience Appoints Liam Taylor as CEO
Author(s)Pharmaceutical Technology Editors
The company has appointed Liam Tayler as CEO to guide the growth of the company’s iPSC technologies, products, and services.
Advertisement
Cambridge, UK-based Axol Bioscience, a biotechnology company specializing in cell-based assay systems derived from stem cell technology for drug discovery, has appointed Liam Taylor as CEO to guide the growth of the company by focusing on its induced pluripotent stem cell (iPSC) technologies, products and services and by maximizing team potential, Axol announced in an Aug. 26, 2020 press release.
Liam is highly experienced with extensive knowledge of running commercial, operations, finance, and innovation teams in the diagnostic, pharma, and life science sector, both in the United Kingdom and the United States. He was previously chief financial officer, then managing director, of BBI Solutions. During Liam’s tenure at BBI solutions, the company’s annual revenues grew from £23 million (US$31 million) to over £52 million (US$69 million), driven by organic growth and strategic acquisitions.
“The Board is delighted to appoint Liam as Axol’s new CEO. His wealth of experience and comprehensive knowledge of the pharma and life science sector will be invaluable in unlocking the full potential of the [c]ompany,” said Jonathan Milner, chairman, Axol Bioscience, in the company press release.
“The progress achieved at Axol Bioscience in developing high quality and consistent iPSCs has been impressive, and I am excited to be joining at an exciting point in the [c]ompany’s development, where we will be working to scale up operations to support the rapidly growing biotech and pharmaceutical markets, to support increases in efficiency within drug screening and discovery,” Taylor added in the press release.
Source:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Can Continuous Tableting End Scale-Up for Complex Oral Drugs?
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
What the Olanzapine Depot Approval Means for CMC Teams
5